A trial investigating GBT-440 in sickle cell disease (SCD) patients with HbSC and HbSbeta+ thalassemia genotypes

Trial Profile

A trial investigating GBT-440 in sickle cell disease (SCD) patients with HbSC and HbSbeta+ thalassemia genotypes

Planning
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs GBT 440 (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2016 New trial record
    • 29 Mar 2016 According to a Global Blood Therapeutics media release, this trial is expected to start in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top